Some Clinical Advances in Pediatric Systemic Lupus Erythematosus

CHEN Qiu-ping,WANG Pei-guang,YANG Sen,ZHANG Xue-jun
DOI: https://doi.org/10.3760/cma.j.issn.1673-4173.2007.06.010
2007-01-01
International Journal of Dermatology and Venereology
Abstract:Pediatric systemic lupus erythematosus (pSLE) is a multi-system autoimmune disease caused by the interplay of environmental, sex hormonal and genetic factors. In general, pSLE tend to have an earlier involvement of organ and more aggressive clinical course compared with adult SLE. The treatment of pSLE varies with the disease severity and organ involvement degree. Corticosteroids and immuno-suppressants are the primary choices for pSLE therapy. Cyclophosphamide (CTX) can effeciently prevent the occurrence of chronic renal failure. Cyclosporine A, mizoribine and rituxima are recommended for CTX-resisting pSLE patients.
What problem does this paper attempt to address?